首页> 美国卫生研究院文献>Springer Open Choice >Confirmation of diosmetin 3-O-glucuronide as major metabolite of diosmin in humans using micro-liquid-chromatography–mass spectrometry and ion mobility mass spectrometry
【2h】

Confirmation of diosmetin 3-O-glucuronide as major metabolite of diosmin in humans using micro-liquid-chromatography–mass spectrometry and ion mobility mass spectrometry

机译:使用微液相色谱-质谱法和离子迁移质谱法确定地奥司汀3-O-葡糖醛酸是人中地诺素的主要代谢产物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Diosmin is a flavonoid often administered in the treatment of chronic venous insufficiency, hemorrhoids, and related affections. Diosmin is rapidly hydrolized in the intestine to its aglicone, diosmetin, which is further metabolized to conjugates. In this study, the development and validations of three new methods for the determination of diosmetin, free and after enzymatic deconjugation, and of its potential glucuronide metabolites, diosmetin-3-O-glucuronide, diosmetin-7-O-glucuronide, and diosmetin-3,7-O-glucuronide from human plasma and urine are presented. First, the quantification of diosmetin, free and after deconjugation, was carried out by high-performance liquid chromatography coupled with tandem mass spectrometry, on an Ascentis RP-Amide column (150 × 2.1 mm, 5 μm), in reversed-phase conditions, after enzymatic digestion. Then glucuronide metabolites from plasma were separated by micro-liquid chromatography coupled with tandem mass spectrometry on a HALO C18 (50 × 0.3 mm, 2.7 μm, 90 Å) column, after solid-phase extraction. Finally, glucuronides from urine were measured using a Discovery HSF5 (100 × 2.1 mm, 5 μm) column, after simple dilution with mobile phase. The methods were validated by assessing linearity, accuracy, precision, low limit of quantification, selectivity, extraction recovery, stability, and matrix effects; results in agreement with regulatory (Food and Drug Administration and European Medicines Agency) guidelines acceptance criteria were obtained in all cases. The methods were applied to a pharmacokinetic study with diosmin (450 mg orally administered tablets). The mean Cmax of diosmetin in plasma was 6,049.3 ± 5,548.6 pg/mL. A very good correlation between measured diosmetin and glucuronide metabolites concentrations was obtained. Diosmetin-3-O-glucuronide was identified as a major circulating metabolite of diosmetin in plasma and in urine, and this finding was confirmed by supplementary experiments with differential ion-mobility mass spectrometry.
机译:薯皂素是一种类黄酮,通常用于治疗慢性静脉功能不全,痔疮和相关疾病。薯os皂素在肠中被迅速水解成其甘草酮薯di皂素,后者被进一步代谢成结合物。在这项研究中,开发了三种新方法,用于测定游离和酶解结合后的薯os皂素,及其潜在的葡糖醛酸代谢产物,薯os皂苷-3-O-葡糖醛酸,薯os皂素-7-O-葡糖醛酸和薯os皂素-呈现了来自人血浆和尿液的3,7-O-葡糖醛酸。首先,在反相条件下,通过高效液相色谱结合串联质谱法在Ascentis RP-Amide色谱柱(150×2.1 mm,5μm)上对游离和解偶联后的Diosmetin进行定量,酶消化后。固相萃取后,在HALO C18(50×0.3 mm,2.7μm,90Å)色谱柱上,通过微液相色谱-串联质谱分离血浆中的葡萄糖醛酸代谢产物。最后,在用流动相简单稀释后,使用Discovery HSF5(100××2.1mm,5μm)色谱柱测量尿液中的葡萄糖醛酸苷。通过评估线性,准确性,精密度,定量下限,选择性,提取回收率,稳定性和基质效应来验证这些方法。在所有情况下均获得了与监管机构(食品药品管理局和欧洲药品管理局)指南接受标准一致的结果。将该方法应用于含有地高辛(450 mg口服片剂)的药代动力学研究。血浆中Diosmetin的平均Cmax为6,049.3±5,548.6pg / mL。测得的薯di皂素和葡萄糖醛酸代谢物浓度之间具有很好的相关性。 Diosmetin-3-O-葡萄糖醛酸苷是血浆和尿液中Diosmetin的主要循环代谢产物,这一发现已通过差动离子淌度质谱的补充实验得到证实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号